206 related articles for article (PubMed ID: 34750990)
1. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
Brendel K; Bekaii-Saab T; Boland PM; Dayyani F; Dean A; Macarulla T; Maxwell F; Mody K; Pedret-Dunn A; Wainberg ZA; Zhang B
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1550-1563. PubMed ID: 34750990
[TBL] [Abstract][Full Text] [Related]
2. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
3. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
[TBL] [Abstract][Full Text] [Related]
4. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
6. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
7. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
8. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
Milano G; Innocenti F; Minami H
Cancer Sci; 2022 Jul; 113(7):2224-2231. PubMed ID: 35445479
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients.
Hamaguchi T; Tsuji A; Yamaguchi K; Takeda K; Uetake H; Esaki T; Amagai K; Sakai D; Baba H; Kimura M; Matsumura Y; Tsukamoto T
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1021-1029. PubMed ID: 30284603
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer.
Bien H; Mackenzie GG; Choi M
Recent Pat Anticancer Drug Discov; 2016; 11(4):376-383. PubMed ID: 27480831
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
13. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
Kim GP; Surinach A; Corvino FA; Cockrum P; Belanger B; Abushahin L
Future Oncol; 2021 Feb; 17(6):675-688. PubMed ID: 33070660
[No Abstract] [Full Text] [Related]
15. Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment.
Basso J; Schwartsmann G; Ibaldi MR; Schaefer VD; Pavei CC; Hahn RZ; Antunes MV; Linden R
J Gastrointest Cancer; 2023 Jun; 54(2):589-599. PubMed ID: 35710870
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
17. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
19. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]